Hisashi Noma

ORCID: 0000-0002-2520-9949 · 4 papers in corpus
other 2023
Evaluation of the Characteristics of Ovarian Endometriomas in Patients with Endometriosis: Efficacy of a Low-Dose Estrogen/Progestogen Combination
Gynecologic and obstetric investigation ·doi:10.1159/000534666

OBJECTIVES: Approximately 17-44% of women diagnosed with endometriosis have ovarian endometriomas (cysts). Although ovarian endometriomas may adversely affect quality of life and work performance, the associations among patient characterist…

2023
Supplementary Material for: Evaluation of the characteristics of ovarian endometrioma in patients with endometriosis: efficacy of a low-dose estrogen/progestogen combination
·doi:10.6084/m9.figshare.24547369

Objectives: Approximately 17–44% of women diagnosed with endometriosis have ovarian endometriomas (cysts). Although ovarian endometriomas may adversely affect quality of life and work performance, no reports have been published on the relat…

nonrandomized-trial 2017
SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial
Yonago acta medica ·doi:10.24563/yam.2017.12.003

BACKGROUND: SR-16234 is a selective estrogen receptor modulator (SERM) structurally different from approved SERM and has been reported to have estrogen receptor (ER) α antagonistic activity and strong affinity with a weak partial agonistic …

nonrandomized-trial 2017
SR-16234, a Novel Selective Estrogen Receptor Modulator for Pain Symptoms with Endometriosis: An Open-label Clinical Trial
·doi:10.33160/yam.2017.12.003

Background SR-16234 is a selective estrogen receptor modulator (SERM) structurally different from approved SERM and has been reported to have estrogen receptor (ER) α antagonistic activity and strong affinity with a weak partial agonistic a…